Association between copeptin and declining glomerular filtration rate in people with newly diagnosed diabetes. The Skaraborg Diabetes Register

AimsCopeptin has shown association with development of chronic kidney disease (CKD) in people with diabetes. Early detection of individuals having the highest risk could help avoid this complication. Therefore we decided to study copeptin concentrations and estimated glomerular filtration rate (eGFR) retrospectively in people with newly diagnosed diabetes.MethodsPeople with newly diagnosed type 2 diabetes in 1996-1998 from Skaraborg Diabetes Register (SDR) were reinvestigated in 2008-2010. Copeptin concentration at the time of diagnosis was determined. Creatinine and cystatin C were used for determination of eGFR at baseline and at reinvestigation (n = 161). Data on cardiovascular complications were extracted from national registers. Analyzes were done with logistic regression.ResultsFrom baseline to follow up eGFR decreased with 33 ml. Twenty-nine individuals (18.1%) developed CKD stage 3. There was a significant association between elevated copeptin concentrations and development of CKD stage 3 (OR = 1.78, 95% CI = 1.01-3.16). When adjusting for GFR at baseline the association between copeptin and GFR decline was borderline significant (OR = 1.79, 95% CI = 0.99-3.25, p = 0.055).ConclusionsDetermination of copeptin may early identify people with diabetes and high risk for CKD. To prevent complications for these individuals aggressive treatment should be discussed.